[print]   [close]
MC2 THERAPEUTICS A/S
BIOTECHGATE BY VENTURE VALUATION
Latest up-date: 02 Sep 2023
GENERAL INFORMATION
 
Agern Alle 24-26
2970 Hørsholm
Denmark
Contact person Mr. Jesper J. Lange, President & Chief Executive Officer
Company main phone +45 (20) 181111
Website https://www.mc2therapeutics.com
Founded (year) 2006
Source of foundation Independent foundation
   
Corporate description / mission
MC2 Therapeutics is a commercial stage pharmaceutical company engaged in the development of novel treatment paradigms for people with immune-mediated conditions with an initial focus on manifestations in the skin. The company's product Wynzora®️ Cream is a novel topical treatment for plaque psoriasis in adults uniquely formulated using PAD Technology™.
State of ownership Private / independent
Headquarters HQ: Yes
CATEGORIZATION  
Main sector Biotechnology - Therapeutics and Diagnostics
Subsector(s)
  • Peptides
  • Small molecules
Primary therapeutic area(s)
  • Diseases of the eye / ophthalmology
  • Skin and subcutaneous tissue / dermatology
  • Genitourinary system / Urology
 
Business model
  • Supplier / Distributor
  • Manufacturer
  • R&D
Customer segments
  • Large biotech & big pharma
  • Small biotech
  • Physicians / doctors
  • Hospitals
SUMMARY PRODUCTS / SERVICES / TECHNOLOGIES  
No. of Biotech Products Pre-clinical Phase I Phase II Phase III On the market
  n/a 1 2 1 1
Description of products
WYNZORA®
MC2-25 CKD-aP (PAD™ Cream), etc.
Technology used
PAD™ Technology

 
ASK OUR LIFE SCIENCE EXPERT IN THE DANISH MARKET
Did you find what you were looking for? If not, feel free to contact us. We have in-depth knowledge of the biotech- and pharma industry, company pipelines and partnering opportunities in Medicon Valley.
 
Get in touch:
All fields are required.

Consultant: Niels Thun Andersen
Name:
Company:
E-Mail Address:
Subject:
Message:
CAPTCHA code

Please enter the above code into the field below.


 
 
© 2024 Venture Valuation  |  Impressum  |  Terms of Use & Privacy Policy  |  Print